RTEZ: Rest EZ, Inc. Stock

by  •  • Comments Off on RTEZ: Rest EZ, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 27.54
Enterprise Value ($M) 27.55
Book Value ($M) -0.05
Book Value / Share -0.00
Price / Book -576.63
NCAV ($M) -0.05
NCAV / Share -0.00
Price / NCAV -576.63

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -167.07
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.00
Current Ratio 0.05

Balance Sheet (mrq) ($M)
Current Assets 0.00
Assets 0.00
Liabilities 0.05
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended December 31, 2023 ☐ Transition report under Section
2024-01-16 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended September 30, 2023 ☐ Transition report under Sectio
2023-09-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended June 30, 2023 ☐ Transition report under Section 13
2023-09-13 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTIO
2023-09-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION

(click for more detail)

Similar Companies
RGTPQ – RegenETP, Inc. RSCI – Redwood Scientific Technologies, Inc.
RSPI – RespireRx Pharmaceuticals Inc. RTSL – Rapid Therapeutic Science Laboratories, Inc.
RVLPQ – RVL Pharmaceuticals plc


Financial data and stock pages provided by
Fintel.io